Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024
[107 Pages Report] The regenerative medicine market is projected to reach USD 38.7 billion by 2024 from USD 13.3 billion in 2019, at a CAGR of 23.8%. Market growth is largely driven by the rising prevalence of chronic diseases and genetic disorders, growing government investments in regenerative medicine research, and the increasing number of regenerative medicine companies globally.
Cell-based immunotherapy & cell therapy products accounted for the largest share of the market in 2019
ased on type, the market is segmented into cell-based immunotherapy & cell therapy products, gene therapy products, and tissue-engineered products. The cell-based immunotherapy & cell therapy products segment dominated this market in 2019. Increasing research and funding and the rising adoption of cell-based immunotherapies for the treatment of cancer are the major factors driving the growth of this market segment
Increasing use of regenerative medicine in musculoskeletal disorders in 2019
The global regenerative medicine industry is segmented, by applications, into musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, and other applications. In 2019, the musculoskeletal disorders segment accounted for the largest market share. The large share of this segment can be attributed to the increasing prevalence of orthopedic diseases, rising geriatric population, increasing number of stem cell research projects, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders
North America to grow at the highest rate during the forecast period (20192024)
The regenerative medicine market in North America is expected to grow at a rapid pace in the coming years. There has been a tremendous increase in cell-based research activities in the past decade. Increasing research activities in the field of regenerative medicine and growing awareness of personalized medicine have also resulted in the establishment of Stem Cell Banking and tissue engineering. North America has both public and private banks that store a limited number of cells and tissues.
Key Market Players
The major players in this market are Kite Pharma (US), Novartis (Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US). Product launches and acquisitions are the key growth strategies followed by most players in this market.
Recent developments:
- In 2018, Novartis received EU approval for one-time gene therapy Luxturna, which has been developed to restore vision in people with rare and genetically-associated retinal disease
- In 2018, Novartis received EU approval for its CAR-T cell therapy, Kymriah.
- In 2017, Integra LifeSciences launched its product, Integra Dermal Regeneration Template Single Layer "Thin" for dermal repair defects reconstruction in a one-step procedure.
Key Questions Addressed in the Report:
- What are the growth opportunities in the regenerative medicine market across major regions in the future?
- Emerging countries have immense opportunities for the growth and adoption of regenerative medicine products. Will this scenario continue during the next five years?
- Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?
- What are the various regenerative medicine types and their respective market shares in the overall market?
- What are the new trends and advancements in the regenerative medicine market?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 13)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Stakeholders
2 Research Methodology (Page No. - 16)
2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.2 Primary Data
2.2.1 Key Data From Primary Sources
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Market Breakdown and Data Triangulation
2.5 Assumptions for the Study
3 Executive Summary (Page No. - 23)
4 Premium Insights (Page No. - 26)
4.1 Regenerative Medicine: Market Overview
4.2 Regenerative Medicine Market, By Type & Application (2019)
4.3 Geographical Snapshot of the Market
5 Market Overview (Page No. - 29)
5.1 Introduction
5.2 Clinical Trials for Regenerative Medicine
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rising Prevalence of Chronic Diseases and Genetic Disorders
5.3.1.2 Rising Government Investments in Regenerative Medicine Research
5.3.1.3 Product Approvals and Growing Pipeline of Regenerative Medicine Products
5.3.2 Restraints
5.3.2.1 Ethical Concerns Related to the Use of Embryonic Stem Cells in Research & Development
5.3.3 Opportunities
5.3.3.1 Implementation of the 21st Century Cures Act
5.3.3.2 Rising Demand for Organ Transplantation
6 Regenerative Medicine Market, By Type (Page No. - 35)
6.1 Introduction
6.2 Cell-Based Immunotherapy & Cell Therapy Products
6.2.1 Allogeneic Products
6.2.2 Autologous Products
6.3 Tissue-Engineered Products
6.4 Gene Therapy Products
7 Regenerative Medicine Market, By Application (Page No. - 43)
7.1 Introduction
7.2 Musculoskeletal Disorders
7.2.1 Musculoskeletal Disorders Segment Will Continue to Dominate the Regenerative Medicine Market in 2024
7.3 Wound Care
7.3.1 Increasing Prevalence of Target Conditions to Drive the Growth of This Application Segment
7.4 Oncology
7.4.1 Increasing Prevalence of Cancer to Support Market Growth
7.5 Ocular Disorders
7.5.1 Growing Number of Product Approvals to Support Market Growth
7.6 Diabetes
7.6.1 Increasing Incidence of Diabetes and the Growing Focus of Companies on Developing Regenerative Medicine for the Treatment of Diabetes are the Key Factors Driving Market Growth
7.7 Other Applications
8 Regenerative Medicine Market, By Region (Page No. - 52)
8.1 Introduction
8.2 North America
8.2.1 US
8.2.1.1 US Accounts for the Largest Share of the Market in North America
8.2.2 Canada
8.2.2.1 Increasing R&D Funding for Regenerative Medicine is A Key Factor Influencing the Growth of the Canadian Market
8.3 Europe
8.3.1 UK
8.3.1.1 UK Accounts for the Largest Market Share in the European Market
8.3.2 Germany
8.3.2.1 Germany has A Strong Foundation for R&D, Including Over 1,000 Public and Private Institutions
8.3.3 France
8.3.3.1 Rising R&D Expenditure, A Major Growth Driver in France
8.3.4 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.1.1 Comparatively Lenient Regulations and Rising Geriatric Population Will Drive Market Growth
8.4.2 China
8.4.2.1 Favorable Investments and Government Support Will Contribute to the Growth of the Chinese Market
8.4.3 Australia
8.4.3.1 Strong Research Base and Availability of Funds Will Push Market Growth in Australia
8.4.4 RoAPAC
8.5 Rest of the World
9 Competitive Landscape (Page No. - 79)
9.1 Overview
9.2 Market Ranking Analysis, 2017
9.3 Key Strategies
9.3.1 Product Launches
9.4 Competitive Leadership Mapping (2018)
9.4.1 Vendor Inclusion Criteria
9.4.2 Visionary Leaders
9.4.3 Innovators
9.4.4 Dynamic Differentiators
9.4.5 Emerging Companies
9.5 Competitive Leadership Mapping for Start-Ups (2018)
9.5.1 Progressive Companies
9.5.2 Starting Blocks
9.5.3 Responsive Companies
9.5.4 Dynamic Companies
10 Company Profiles (Page No. - 86)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
10.1 Novartis AG
10.2 Vericel
10.3 Integra Lifesciences
10.4 Mimedx Group
10.5 Stryker
10.6 Wright Medical
10.7 Spark Therapeutics
10.8 Osiris Therapeutics
10.9 Kite Pharma (Subsidiary of Gilead Sciences)
10.10 Organogenesis
*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.
11 Appendix (Page No. - 103)
11.1 Insights From Industry Experts
11.2 Discussion Guide
11.3 Available Customizations
11.4 Related Reports
11.5 Author Details
List of Tables (76 Tables)
Table 1 Few Important Clinical Studies in the Regenerative Medicine: Market
Table 2 Cancer Incidence and Mortality, By Region, 20122035
Table 3 Funding for Regenerative Medicine Research By the Nih Under the 21st Century Cures Act
Table 4 Nih Funding for Regenerative Medicine Research in the Us, 20142016 (USD Million)
Table 5 California Institute of Regenerative Medicine Funding for Regenerative Medicine Research
Table 6 Number of Companies Operating in the Regenerative Medicine: Market, By Region (20142018)
Table 7 Market, By Type, 20172024 (USD Billion)
Table 8 Few of the Commercialized Cell-Based Immunotherapy & Cell Therapy Products
Table 9 Cell-Based Immunotherapy & Cell Therapy Products Market, By Region, 20172024 (USD Billion)
Table 10 Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 11 Cell-Based Allogeneic Regenerative Medicine
Table 12 Allogeneic Products Market, By Region, 20172024 (USD Billion)
Table 13 Cell-Based Autologous Regenerative Medicine
Table 14 Autologous Products Market, By Region, 20172024 (USD Billion)
Table 15 Few of the Commercialized Tissue-Engineered Products
Table 16 Market for Tissue-Engineered Products, By Region, 20172024 (USD Billion)
Table 17 Few of the Commercialized Gene Therapy Products
Table 18 Market for Gene Therapy Products, By Region, 20172024 (USD Billion)
Table 19 Market, By Application, 20172024 (USD Billion)
Table 20 Market for Musculoskeletal Disorders, By Region, 20172024 (USD Billion)
Table 21 Regenerative Medicine Products Commercialized for the Treatment of Acute & Chronic Wounds
Table 22 Market for Wound Care, By Region, 20172024 (USD Billion)
Table 23 Number of Cancer Patients, By Type, 20122030
Table 24 Indicative List of Commercialized Regenerative Cell-Based Immunotherapies for the Treatment of Cancer
Table 25 Market for Oncology, By Region, 20172024 (USD Billion)
Table 26 Market for Ocular Disorders, By Region, 20172024 (USD Billion)
Table 27 Market for Diabetes, By Region, 20172024 (USD Billion)
Table 28 Market for Other Applications, By Region, 20172024 (USD Billion)
Table 29 Market, By Region, 20172024 (USD Billion)
Table 30 North America: Market, By Country, 20172024 (USD Billion)
Table 31 North America: Market, By Type, 20172024 (USD Billion)
Table 32 North America: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 33 North America: Regenerative Medicine, By Application, 20172024 (USD Billion)
Table 34 Products With Rmat Designation (As of 2018)
Table 35 US: Market, By Type, 20172024 (USD Billion)
Table 36 US: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 37 US: Market, By Application, 20172024 (USD Billion)
Table 38 Canada: Market, By Type, 20172024 (USD Billion)
Table 39 Canada: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 40 Canada: Market, By Application, 20172024 (USD Billion)
Table 41 Research Funding European Overview
Table 42 Europe: Market, By Country, 20172024 (USD Billion)
Table 43 Europe: Market, By Type, 20172024 (USD Billion)
Table 44 Europe: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 45 Europe: Regenerative Medicine, By Application, 20172024 (USD Billion)
Table 46 UK: Market, By Type, 20172024 (USD Billion)
Table 47 UK: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 48 UK: Market, By Application, 20172024 (USD Billion)
Table 49 Germany: Market, By Type, 20172024 (USD Billion)
Table 50 Germany: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 51 Germany: Market, By Application, 20172024 (USD Billion)
Table 52 France: Market, By Type, 20172024 (USD Billion)
Table 53 France: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 54 France: Market, By Application, 20172024 (USD Billion)
Table 55 RoE: Market, By Type, 20172024 (USD Billion)
Table 56 RoE: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 57 RoE: Market, By Application, 20172024 (USD Billion)
Table 58 APAC: Market, By Country, 20172024 (USD Billion)
Table 59 APAC: Market, By Type, 20172024 (USD Billion)
Table 60 APAC: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 61 APAC: Market, By Application, 20172024 (USD Billion)
Table 62 Japan: Market, By Type, 20172024 (USD Billion)
Table 63 Japan: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 64 Japan: Market, By Application, 20172024 (USD Billion)
Table 65 China: Market, By Type, 20172024 (USD Billion)
Table 66 China: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 67 China: Market, By Application, 20172024 (USD Billion)
Table 68 Australia: Market, By Type, 20172024 (USD Billion)
Table 69 Australia: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 70 Australia: Market, By Application, 20172024 (USD Billion)
Table 71 RoAPAC: Market, By Type, 20172024 (USD Billion)
Table 72 RoAPAC: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 73 RoAPAC: Market, By Application, 20172024 (USD Billion)
Table 74 RoW: Market, By Type, 20172024 (USD Billion)
Table 75 RoW: Cell-Based Immunotherapy & Cell Therapy Products Market, By Type, 20172024 (USD Billion)
Table 76 RoW: Market, By Application, 20172024 (USD Billion)
List of Figures (29 Figures)
Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market: Bottom-Up Approach
Figure 4 Market: Top-Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 Market, By Type, 2019 vs 2024 (USD Billion)
Figure 7 Market, By Application, 2019 vs 2024 (USD Billion)
Figure 8 Market, By Region, 2019 vs 2024 (USD Billion)
Figure 9 Growing Government Investments in Regenerative Medicine Research to Drive Market Growth During the Forecast Period
Figure 10 Musculoskeletal Disorders to Dominate the Regenerative Medicine: Market in 2019
Figure 11 Countries in Europe to Register A Higher Growth Rate During the Forecast Period
Figure 12 Market: Drivers, Restraints, and Opportunities
Figure 13 Cell-Based Immunotherapy & Cell Therapy Products Segment to Dominate the Market in 2018
Figure 14 Oncology Segment to Register the Highest Growth in the Regenerative Medicine Market During the Forecast Period
Figure 15 Prevalence of Diabetes, By Region, 2015 vs 2040
Figure 16 North America to Witness the Highest Growth in the Regenerative Medicine Market During the Forecast Period
Figure 17 Investment Levels Quadrupled During 20102016
Figure 18 North America: Market Snapshot
Figure 19 Key Developments in the Market
Figure 20 Regenerative Medicine Market Ranking, By Key Player, 2018
Figure 21 MnM Dive-Vendor Comparison Matrix: Market
Figure 22 MnM Dive-Vendor Comparison Matrix for Start-Ups: Regenerative Medicine Market
Figure 23 Novartis: Company Snapshot
Figure 24 Vericel: Company Snapshot
Figure 25 Integra Lifesciences: Company Snapshot
Figure 26 Mimedx Group: Company Snapshot
Figure 27 Stryker : Company Snapshot
Figure 28 Wright Medical: Company Snapshot
Figure 29 Osiris Therapeutics: Company Snapshot
The study involved four major activities to estimate the current size of the regenerative medicine market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
Several stakeholders such as regenerative medicine manufacturers, vendors, distributors and scientists, researchers, laboratory technicians, and doctors from hospitals and clinics were consulted for this report. The demand side of this market is characterized by significant use of regenerative medicine due to increasing cancer, diabetes, chronic wounds, musculoskeletal disorders and the growing aging population across the globe. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the regenerative medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industrys supply chain and market size, in terms of value, have been determined through primary and secondary research processes
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market sizeusing the market size estimation processesthe market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the regenerative medicine industry.
Report Objectives
- To define, describe, and forecast the regenerative medicine market on the basis of type, application, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities)
- To strategically analyse micromarkets with respect to individual growth trends, prospects, and contributions to the overall regenerative medicine market
- To analyse market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments in four geographical regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
- To profile the key players and comprehensively analyse their product portfolios, market positions, and core competencies
- To track and analyse competitive developments such as product launches, partnerships, expansions, and acquisitions in the regenerative medicine market
Scope of the Report
|
Report Metric |
Details |
|
Market Size Available for Years |
20172024 |
|
Base Year Considered |
2018 |
|
Forecast Period |
20192024 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Regenerative medicine type, applications, and regions |
|
Geographies Covered |
North America (US, Canada), Europe (Germany, France, UK and the RoE), APAC (Japan, China, Australia, and the RoAPAC), and RoW |
|
Companies Covered |
Major 10 players covered, including: Kite Pharma (US), Novartis (Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US). |
This research report categorizes the regenerative medicine market into the following segments and subsegments:
Regenerative Medicine Market, by Type
- Cell-Based Immunotherapy & Cell Therapy Products
- Allogeneic Products
- Autologous Products
- Gene Therapy Products
- Tissue-Engineered Products
Regenerative Medicine, by Application
- Musculoskeletal Disorders
- Wound Care
- Oncology
- Ocular Disorders
- Diabetes
Regenerative Medicine market, by Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- Australia
- Rest of Asia Pacific
- Rest of the World
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the report:
- Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
- Geographic Analysis: Further breakdown of the European, Asia Pacific, and the Rest of the World segments into their respective countries for this market
- Company Information: Detailed analysis and profiling of additional market players (up to 5)
- Volume Data: Customization options for volume data (number of units sold) and customization options for volume data (number of tests)
- Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Regenerative Medicine Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Regenerative Medicine Market